Mark Hooper Consulting

Scientific consulting for IP lawyers

Mark Hooper Consulting was set up in 2017 to focus on developing the support work for IP lawyers that Dr Mark Hooper had already been providing over the previous 10 years. In recent years, Mark has carried out many major practical projects providing results and data in organic chemistry, product characterisation, formulation (finished product), analysis & stability and food science (tasting and ingredient stability); and provided direct technical support including writing experimental protocols, researching precedent and common general knowledge at the filing date of the patent, and helping the general understanding of the science in complex patents (e.g. Markush structures, drug naming, organic chemistry, formulations, explaining analytical data, etc.).

Dr Mark Hooper: Background and CV

Dr Mark Hooper offers expert scientific support to IP lawyers to improve the quality of the information and understanding available for your case. With first-class scientific qualifications from Oxford and Yale Universities, an MBA from Warwick and over 15 years’ experience in the pharmaceutical development industry, Mark will bring industry and real-world experience combined with world-class scientific knowledge to your team. He can support you with a deep and rapid understanding and clear explanation of the science behind the IP/patent challenges.

Mark previously worked for Pharmaterials for 8 years (a full formulation development and GMP manufacturing company, with expertise in characterisation of drug physical forms and polymorphs), and Johnson Matthey for 7 years (a precious metal company with specific expertise in catalysis, chirality and full drug synthesis).

Mark has been involved with many patent cases working with, amongst others, Elkington Fife, Pinsent Mason, GJE, D Young & Co, HGF, Olswang (now CMS), SJ Berwin, Bird & Bird, 8 New Square, Powell Gilbert, Taylor Wessing, Goodwin Proctor, FLH and Cabinet Tripoz (Lyon).

Projects have included top-selling drugs such as Esomeprazole (Nexium), Atorvastatin (Lipitor), Escitalopram (Cipralex) and Modafinil (Provigil) and more general cases involving inhalation products (lactose, inhalers, formulations, etc.), polymorphs, amorphous material and chiral catalysis.